MAIA Biotechnology, Inc. (MAIA) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Chicago, IL, 미국. 현재 CEO는 Vlad Vitoc.
MAIA 을(를) 보유 IPO 날짜 2022-07-28, 13 명의 정규직 직원, 에 상장 NYSE, 시가총액 $54.9M.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
